Caffeine citrate has been implemented to some extent worldwide withinneonatal units for preterm baby’s obstructive sleep apnea management. Almost, preterm babies are prone to obstructive sleep apnea, plus elevated death risk or even disabilities. Up to date, caffeine citrate is addressed for preterm babies` apnea targeting to reduce bronchopulmonary dysplasia incidence, as well neurodevelopmental disability at 18-21 months. Caffeine citrate is recognized to havelong-term safety, particularlyrelating to motor, behavioral, and intelligence skills. Prenatal caffeine predisposes to intrauterine growth restriction and small growth for gestational age at birth. Caffeine citratehas a cost-effective pharmacotherapy benefit, in terms of safety, and efficacy for preterm babies’ apnea, and modulating rates of bronchopulmonary dysplasia within neonatal intensive care units.
